Regardless of your aging, lifestyle, weight, or genetic concerns, you deserve to look as young and healthy as you feel. You should be able to look into the mirror every morning and feel inspired to live life more fully. CUTERA Australia & New Zealand is committed to delivering what you need, by enabling cutting-edge solutions within the medical aesthetics industry.
Brett Elliott, General Manager at CUTERA highlights the growing need for medical aesthetics in recent years. He says, “With society and technology evolving, I like to believe that non-surgical medical aesthetics can be leveraged as a lever to help restore and maintain one’s natural beauty, increase confidence and self-esteem, and maybe just have some form of positive impact on mental health, which is an increasingly alarming issue for society in recent times.”
Thus, CUTERA, in partnership with physicians, offers a full suite of treatment options to help meet your patient’s needs. From vascular conditions to pigmentation, tattoo and body sculpting, CUTERA provides tailored solutions with its best-in-class devices that are exquisitely engineered to deliver the highest level of performance, safety and efficacy.
In addition, while technology is undeniably a core aspect of growth within the industry of medical aesthetics, it is the customers’ success that determines the value of a service. CUTERA has taken this principle seriously. The company prioritizes customer service over having great technology, by investing in recruiting people who can support its customers in their journey to success. Functioning on such a value is what makes CUTERA deserving of the title, “Top 5 Leading Companies in Medical Aesthetics Market 2023.”
Let’s dive in to learn about CUTERA’s operations that sets it apart in the medical aesthetics industry.
CUTERA’s Wide Range of Aesthetic Solutions
CUTERA has a portfolio that is the envy of many. “Our innovative laser and light-based technology provide a wide range of aesthetic solutions for conditions including all things vascular, pigment, skin revitalization and many more including rosacea, melasma diffuse redness, tattoos, and the list goes on to more than 30 approved indications.”
CUTERA also possesses the award-winning, market-leading truBody devices truSculpt and truFlex to remove fat and build muscle in simple, easy to use 15 minutes treatments.
Research, Innovation and Customer Satisfaction
CUTERA has a robust consultative process for understanding its customers’ clinical and technical requirements before embarking on the journey to deliver innovation to the market. “What sets us apart from other medical aesthetics services in the market is our focus on innovation, research and customer satisfaction. We work closely with our global and local customers to understand their needs and provide tailored solutions to address their specific requirements,” says Brett.
Strategic collaborations like this with opinion-leading customers saw the evolution of Excel V+ (designed by Dermatologists for Dermatologists) and the truSculpt – designed based on feedback from customers on what they wanted to see in the ideal non-invasive body contouring platform.
Brett continues, “We collaborate with our customers and understand their specific needs and preferences. We then leverage our extensive research and development capabilities to design and manufacture products that meet their needs. We also conduct extensive clinical trials to ensure that our products are safe, effective, and meet regulatory requirements with FDA, TGA, NZ MedSafe and other global regulatory bodies.”
CUTERA’s portfolio is the envy of many in the medical aesthetics industry. In summary, it possesses an elite vascular portfolio. The Excel V+ is the latest generation laser technology to address a wide range of vascular and pigment concerns. Excel V+ delivers the power, precision and performance to safely and effectively treat a wide range of indications from challenging vascular and pigmentary conditions to today’s most common skin concerns. The Excel V+ also delivers CUTERA’s patented Laser Genesis treatment that continues to be delivered with the 1064nm wavelength and also now in the form of green genesis via the 532nm wavelength.
To complement the vascular portfolio, CUTERA has Enlighten III, an innovative and versatile picosecond and nanosecond technology with 3x separate leading wavelengths (1064nm, 532nm plus the unique 670nm wavelength) all interchangeable at the touch of a button on the interface offering ease of use and cutting edge technology for benign pigmented lesions and PICO genesis, skin rejuvenation. It also enables clinics to remove all colors of tattoos. The company also manufactures the Enlighten SR for skin revitalization, scarring, et cetera, using the 1064nm and the 532nm wavelengths.
CUTERA’s XEO remains a best seller and is a world-class customizable multi-application platform designed to treat the widest range of most common nonsurgical aesthetic concerns such as veins, pigment, wrinkles, hair removal, resurfacing, and skin revitalization with a single, robust device.
The re-invented truBody portfolio of truSculpt and truFlex are both cutting edge non-invasive body contouring technologies that reduce fat and tone muscle. The efficacy and safety of the truBody portfolio are unsurpassed in the medical aesthetics space and both systems offer easy to use 15min treatments to help clinics satisfy the ever-increasing demand for body treatments in what has emerged as one of the fastest growing categories in the medical aesthetics space.
Maintaining the Highest Engineering Standards
Maintaining the highest engineering standards in production and R&D is a top priority at CUTERA. “We have a rigorous quality management system in place to ensure that our products meet the highest standards of safety and effectiveness. Our R&D team is made up of experienced engineers, scientists and medical professionals who work together to develop innovative solutions that meet the needs of practitioners and patients alike. We also invest heavily in the latest manufacturing technologies to ensure that our products are produced efficiently and to the highest standards of quality,” emphasizes Brett.
Turning Challenges into Opportunities for Growth
Being a publicly listed global leading manufacturer in medical aesthetics, CUTERA faces various headwinds to ensure that it continues to design, manufacture and supply best-in-class technology to keep up with global demand. With its systems being manufactured in the US and shipped globally on-demand, at a local ANZ level, the company also collaborates effectively, working in partnership with CUTERA HQ to ensure its ANZ customers remain a priority for CUTERA Inc. “CUTERA ANZ continues to be a flagship business for CUTERA globally due to the quality of technology we promote, the structures we have embedded over the past few years to support our customers and importantly, I am fortunate to have been able to invest in people to build the best team in the medical aesthetics industry,” says Brett.
Despite there being more clutter and competition than ever, CUTERA continues to establish its portfolio as the choice of doctors and other high-quality clinicians whose aim is to invest in the right technology to achieve optimal patient outcomes. This focus on quality outcomes means CUTERA continues to support customers post-sale and help them drive growth in the knowledge that patients are receiving the best treatments available via a CUTERA platform.
He continues. “We strive to stay ahead of the competition by constantly innovating and improving our technology. We also collaborate closely with regulatory agencies by providing the necessary analytical rigor to support our clinical data submissions ensuring optimal approval times. Finally, we maintain financial stability by carefully managing our resources, investing in growth opportunities, and launching new technology into growth markets to instill confidence in our customers that if they invest in CUTERA technology, there will be demand for those treatments.”
Words of Wisdom
To budding entrepreneurs and enthusiasts who desire to venture into the medical aesthetics sector, Brett advises, “Focus on developing innovative, safe and effective technologies that provide solutions for high volume unmet patient needs. I would also encourage them to collaborate with healthcare professionals and patients to develop the best treatment options possible.”
Scaling Operations in 2023 and Beyond
CUTERA has been at the forefront of the medical aesthetics industry for 25 years. Brett adds, “We have consistently delivered innovative and effective solutions to patients and our innovative pipeline suggests the best is yet to come. Our ongoing focus on research and development will continue to help CUTERA stay ahead of the curve.”
“In 2023 and beyond, we will scale our business and structure in a way that allows us to continue to evolve the support we offer customers across Australia and New Zealand and to continue to outgrow predicted double-digit growth across the medical aesthetics industry over the next 5 years and beyond.”
“We also plan to continue collaborating regularly with our customers to ensure that future investments made in technology, training, education and people, are aligned with the needs of our customers and their patients to enhance the strong partnership approach CUTERA prides itself on,” concludes Brett.
Brett Elliott, General Manager in Brief
Although Brett began his professional career as a school teacher and then worked in elite sports, he has been in the pharmaceutical, capital equipment and aesthetic industry for over 20 years, with experience across a broad range of therapeutic areas and held numerous senior leadership positions. His passion is building teams, contributing to the development of his people, and empowering them to be successful.
“I embrace encouraging positive culture change as required as its ultimately the people, and the capabilities and attitude they bring to work each day, that drives the success of any business,” emphasizes Brett.
Before joining CUTERA ANZ, Brett worked for several leading global entities such as Pfizer and Alcon. His journey towards joining CUTERA was driven by his desire to work for a smaller organization that truly values innovation, and communication with customers and empowers him to rebuild the brand across ANZ.
“It was also CUTERA’s unwavering commitment to advancing the field of medical aesthetics and providing innovative solutions to address a wide range of patient concerns that drew me to the company over 5yrs ago now,” he says.
|Next Story: https://insightscare.com/hungry-children-must-be-fed-nutrition-to-save-the-nhs/|